Lunit Expands CRO Partnership With CellCarta to Advance AI Biomarker Development

• Lunit and CellCarta announced a strategic collaboration to accelerate AI-enabled digital pathology for companion diagnostic (CDx) programs.

• The partnership integrates Lunit’s AI pathology tools into CellCarta’s global CRO laboratory and clinical trial workflows. 

Lunit announced a strategic collaboration with CellCarta to accelerate adoption of AI-enabled digital pathology in companion diagnostic development and clinical trials. The partnership combines Lunit’s artificial intelligence-based pathology technologies with CellCarta’s global contract research organization (CRO) laboratory services to support biomarker development and precision medicine programs. 

Under the agreement, Lunit’s SCOPE AI digital pathology solutions will be integrated into CellCarta’s workflows across translational research, clinical trial testing, and companion diagnostic development. The companies said the collaboration is designed to support quantitative image analysis, biomarker strategy development, and CDx readiness for pharmaceutical sponsors. 

CellCarta operates a global network of laboratories and provides biomarker testing and specialty laboratory services for clinical trials. By incorporating AI-enabled pathology tools, the partnership aims to improve scalability, enable standardized biomarker analysis, and support patient stratification in oncology development programs. 

The collaboration also addresses operational challenges such as platform compatibility, global capacity constraints, and site-specific limitations by enabling flexible deployment of AI-driven pathology analysis across multiple trial environments. The companies said this approach is intended to accelerate clinical development timelines and improve decision-making in companion diagnostic programs. 

“By combining Lunit’s AI-powered digital pathology with CellCarta’s global laboratory network, we aim to accelerate the development of companion diagnostics and help bring precision therapies to patients faster.”

Brandon Suh, CEO of Lunit